ProfileGDS5678 / 1453820_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 19% 19% 19% 19% 19% 19% 19% 18% 18% 19% 19% 18% 19% 19% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.486419
GSM967853U87-EV human glioblastoma xenograft - Control 22.4528219
GSM967854U87-EV human glioblastoma xenograft - Control 32.4532219
GSM967855U87-EV human glioblastoma xenograft - Control 42.3997419
GSM967856U87-EV human glioblastoma xenograft - Control 52.4055119
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.5063719
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.4879819
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.4263218
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.418918
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.4379419
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.4369619
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.4142318
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.4473819
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.4419819